Buprenorphine is one of three FDA-approved medications to treat opioid use disorder. According to the Nov. 16 letter, 2.5 million Americans use buprenorphine.
“The allowance of telehealth for treating opioid use disorder is a low-barrier treatment option that presents an opportunity to expand buprenorphine access to populations who may have previously struggled to receive treatment,” the letter said. “Prior to these telehealth flexibilities, many Americans struggled to access buprenorphine treatment initiation due to geographic barriers.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
